🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with select trial: 20% mace reduction? Page 4

Has anyone dealt with select trial: 20% mace reduction?

Dr.SurgeonPGH Thu, Apr 30, 2026 at 6:00 AM 28 replies 808 viewsPage 4 of 6
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
May 5, 2026 at 1:19 AM#16

Clinical perspective, offered as context rather than as advice.

anders_CPH said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

13 13BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 10 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
May 5, 2026 at 5:51 AM#17
DebRD_ATL said:
anders_CPH said: ...we're creating a generation dependent on cardiovascular risk...

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 60 pg/mL (normal, cardiac function preserved)
  • Lp(a): 40 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 135 to 85 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

12 12pam_stl, wei_SG, cory_ATX and 9 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
May 5, 2026 at 10:23 AM#18
DebRD_ATL said:
anders_CPH said: ...we're creating a generation dependent on cardiovascular risk...

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
Last edited: May 5, 2026 at 12:23 PM
11 11zoe_NC, Dr.ObesityLA, NurseKim_ATL and 8 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
May 5, 2026 at 2:55 PM#19
DebRD_ATL said:
anders_CPH said: ...we're creating a generation dependent on cardiovascular risk...

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

10 10robert_kc, dan_philly, MeganSA_TX and 7 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
May 5, 2026 at 7:27 PM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Carry on.

Last edited: May 5, 2026 at 9:27 PM
38 13PurityPaulOR, MaxMetOK, MounjBrad and 35 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register